Near-uniform, low-level conjugation of cytotoxins to antitumor antibodies increases their tolerability without compromising efficacy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Carter, P.J. & Senter, P.D. Cancer J. 14, 154–169 (2008).
Wu, A.M. & Senter, P.D. Nat. Biotechnol. 23, 1137–1146 (2005).
Lambert, J.M. Curr. Opin. Pharmacol. 5, 543–549 (2005).
Damle, N.K. Expert Opin. Biol. Ther. 4, 1445–1452 (2004).
Junutula et al. Nat. Biotechnol. 26, 925–932 (2008).
Sun, M.M. et al. Bioconjug. Chem. 16, 1282–1290 (2005).
McDonagh, C.F. et al. Protein Eng. Des. Sel. 7, 299–307 (2006).
Hamblett, K.J. et al. Clin. Cancer Res. 10, 7063–7070 (2004).
Scott, A.M. et al. J. Clin. Oncol. 26, Abstract 3025, presented at the 44th annual ASCO meeting, Chicago, IL, May 30–June 3, 2008.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Damle, N. Antibody-drug conjugates ace the tolerability test. Nat Biotechnol 26, 884–885 (2008). https://doi.org/10.1038/nbt0808-884
Issue Date:
DOI: https://doi.org/10.1038/nbt0808-884
This article is cited by
-
Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability
Pharmaceutical Research (2015)
-
Strategies and challenges for the next generation of therapeutic antibodies
Nature Reviews Immunology (2010)